2020 BIO Investor Forum Buzz of BIO Finalist
Childhood cancers are complex rare diseases for which only four specific drugs have been approved in the last 40 years. Despite this, there are multiple assets in biopharma companies and academic research centers that hold a real potential to cure several types of childhood cancer.
Oncoheroes is a biotech company 100% focused on discovering, developing and commercializing new therapies for children and adolescents with cancer.
We intend to become the global leader in delivering new pediatric oncology drugs.
We cover the whole drug development spectrum from bench to bed side.
At our discovery lab, we are focused looking for precise pediatric oncogenic targets to developt more effective and less toxic treaments for children with cancer.
In paralel, we are scouting for clinical-stage or near-clinical-stage assets that could be used for some type of childhood cancer. The first licensed asset, Volasertib, has enormous potential to treat Alveolar Rhabdomyosarcoma.
Childhood cancers are complex rare diseases for which only four specific drugs have been approved in the last 40 years. Despite this, there are multiple assets in biopharma companies and academic research centers that hold a real potential to cure several types of childhood cancer.
Oncoheroes is a biotech company 100% focused on discovering, developing and commercializing new therapies for children and adolescents with cancer.
We intend to become the global leader in delivering new pediatric oncology drugs.
We cover the whole drug development spectrum from bench to bed side.
At our discovery lab, we are focused looking for precise pediatric oncogenic targets to developt more effective and less toxic treaments for children with cancer.
In paralel, we are scouting for clinical-stage or near-clinical-stage assets that could be used for some type of childhood cancer. The first licensed asset, Volasertib, has enormous potential to treat Alveolar Rhabdomyosarcoma.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Orphan/Rare Diseases
Lead Product in Development:
Volasertib (in-licensed compound from Boehringer Ingelheim)
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
